Amgen hails cost-saving effect of biosimilars
In Q2 alone, biosimilars have yielded a USD 3.2bn drug spend reduction, according to Amgen, which heralds the rise of the drug class despite the increased competition.
by albert rønning andersson, translated by daniel pedersen
Though Amgen has lost billions of dollars from biosimilars entering the market, the company still praises their development.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
CHMP recommends approval of 12 drugs at September meeting
For subscribers
FDA makes historic ruling on biosimilar insulin
For subscribers
